Pernod Ricard (RI) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
8 Apr, 2026Executive summary
H1 FY26 saw a 5.9% organic net sales decline and 14.9% reported drop, mainly due to softness in the US and China, FX headwinds, and brand disposals, while other regions showed growth and operational efficiency gains.
Operational efficiency program delivered rapid cost reductions, including a 10% drop in structural costs and improved cash generation, with one-third of €1bn target savings expected by FY26.
Free cash flow improved by 9.5% to €482m, supported by normalized strategic investments and strong working capital management.
Portfolio management continued with the disposal of Imperial Blue and other non-core brands.
FY26 is a transition year with a focus on deleveraging, sustainable value growth, and innovation.
Financial highlights
Net sales: €5,253m, down 5.9% organically and 14.9% reported; Q1 down 8%, Q2 down 5%.
Profit from Recurring Operations declined 7.5% organically and 18.7% reported, mainly due to FX.
Gross margin fell 216 bps to 59.3%, impacted by tariffs, inflation, and lower fixed cost absorption.
Free cash flow reached €482m, up 9.5% year-over-year, driven by working capital improvements.
EPS down 20% to €4.04 due to lower reported profit and negative FX.
Outlook and guidance
FY26 outlook unchanged; expects stronger H2 with improving top-line trends and organic net sales growth to accelerate.
Strategic investments revised to €750m for FY26, normalizing to ≤€800m from FY27.
Cash conversion target of 80%+ to be achieved in FY26, one year ahead of plan.
Net debt/EBITDA ratio targeted below 3x by FY29.
FX expected to be a significant headwind for the full year.
Latest events from Pernod Ricard
- Agile pricing, portfolio focus, and wholesaler realignment drive brand momentum and efficiency.RI
Investor Update - Distribution changes and data-driven strategies boost Power Six brands and RTD growth.RI
Investor update (Q&A) - Key brands outperform competitors as innovation and execution drive improved momentum.RI
Investor update - Q3 organic net sales rose 4.1%, but full-year sales are forecast to decline 3–4% amid FX headwinds.RI
Q3 2026 - Q1 organic sales fell 7.6%, but H2 is expected to improve as key markets recover.RI
Q1 2026 - Stable sales, margin gains, and a €4.70 dividend headline a governance-focused AGM.RI
AGM 2024 - Q1 sales declined 5.9% organically, with China and US driving the downturn; guidance unchanged.RI
Q1 2025 - Organic sales down 1%, margins up, net profit down 35%, FY25 growth expected.RI
H2 2024 - Q3 organic net sales fell 3%, but volumes rose and FY25 outlook and dividend were confirmed.RI
Q3 2025